Medication Management of Antipsychotic-Induced Weight Gain in Children and Teens

Dr. Feder: Of approximately one million US children and adolescents, roughly 1% are prescribed second-generation antipsychotics. These medications routinely lead to weight gain in kids and teens even beyond the 7% that the FDA’s calls it’s ‘level of concern’. The worst offenders are olanzapine, quetiapine, and risperidone. Lurasidone and ziprasidone are of less concern, and of course there is every bit of in between including aripiprazole. In this episode, we’ll discuss the efficacy and safety of using off-label medications, such as metformin, to manage metabolic side effects of second-generation antipsychotics. 

Welcome to The Carlat Psychiatry Podcast.

This is another episode from the child psychiatry team. 

I’m Dr. Josh Feder, The Editor-in-Chief of The Carlat Child Psychiatry Report and co-author of The Child Medication Fact Book for Psychiatric Practice and the brand-new book, Prescribing Psychotropics.

Mara: And I’m Mara Goverman, a Licensed Clinical Social Worker in Southern California with a private practice. 

Listen here: https://www.thecarlatreport.com/podcast/medication-management-of-antipsychotic-induced-weight-gain-in-children-and-teens/

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Addressing Weight Stigma in Clinical Practice

Every patient and family you see is inescapably impacted by weight stigma or fat shaming and the damage from this bias can be lethal. In this podcast, Mara and I help your patients to shield themselves from weight stigma with healthier attitudes.

School Inclusion: What You Need to Know

When a school placement is a bad fit, medication and therapy are unlikely to make much difference. In this episode, we will help you understand and assist your patients to optimize their success in the least restrictive placement.